Maymetsi

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a Biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels when used in combination with diet, exercise, and other antidiabetic agents.

GNH USA supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable logistics for global distribution to meet patient needs.

Maymetsi combines metformin and sitagliptin to improve glycemic control in type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves blood glucose levels when added to diet and exercise. - Inadequate control on metformin alone: provides additional glucose‑lowering effect. - Combination therapy with other antidiabetics: enhances overall glycemic management.

Adverse reactions may occur with oral antidiabetic combinations.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: increased stool frequency, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild persistent headache. - Upper respiratory tract infection: nasopharyngitis symptoms. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes. - Anaphylaxis: rare allergic reaction requiring immediate medical attention.

Use of Maymetsi requires careful clinical assessment and monitoring. - Renal function: assess baseline and monitor periodically to avoid accumulation. - Lactic acidosis risk: avoid in patients with severe renal impairment or conditions predisposing to hypoxia. - Pregnancy: consider only if potential benefit justifies potential risk to the fetus. - Hypersensitivity: discontinue if rash, angioedema, or other allergic signs develop. - Drug interactions: review concomitant medications for possible additive effects. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Maymetsi may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure when combined with metformin. - Strong CYP2C9 inhibitors: can increase plasma levels of sitagliptin.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: may enhance risk of hypoglycemia. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: may increase risk of renal impairment. - Alcohol: can potentiate metformin‑associated lactic acidosis. - Anticoagulants: may require dose adjustment due to altered glycemic control.